PDCD1 and melanoma: In 2012, a phase 1 study aimed to assess the safety, anti-tumor activity, and pharmacokinetics of a specific fully human IgG4-blocking mAb directed against PD-1 in patients with advanced solid tumors including melanoma, non–small-cell lung cancer, castration-resistant prostate cancer, and renal-cell and colorectal cancer [41].